These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 23449455

  • 1. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.
    Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, Johnstone RW.
    Cell Death Dis; 2013 Feb 28; 4(2):e519. PubMed ID: 23449455
    [Abstract] [Full Text] [Related]

  • 2. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD.
    BMC Med Genomics; 2009 Nov 30; 2():67. PubMed ID: 19948057
    [Abstract] [Full Text] [Related]

  • 3. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S, López-Guerra M, Saborit-Villarroya I, Rosich L, Campo E, Roué G, Colomer D.
    Clin Cancer Res; 2011 Jun 15; 17(12):3956-68. PubMed ID: 21652541
    [Abstract] [Full Text] [Related]

  • 4. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.
    Labisso WL, Wirth M, Stojanovic N, Stauber RH, Schnieke A, Schmid RM, Krämer OH, Saur D, Schneider G.
    Cell Cycle; 2012 Apr 15; 11(8):1593-602. PubMed ID: 22456335
    [Abstract] [Full Text] [Related]

  • 5. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
    Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, Johnstone RW.
    Mol Cancer Ther; 2008 May 15; 7(5):1066-79. PubMed ID: 18483296
    [Abstract] [Full Text] [Related]

  • 6. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
    Thompson RC, Vardinogiannis I, Gilmore TD.
    PLoS One; 2013 May 15; 8(5):e62822. PubMed ID: 23667527
    [Abstract] [Full Text] [Related]

  • 7. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
    Falkenberg KJ, Newbold A, Gould CM, Luu J, Trapani JA, Matthews GM, Simpson KJ, Johnstone RW.
    Cell Death Differ; 2016 Jul 15; 23(7):1209-18. PubMed ID: 26868908
    [Abstract] [Full Text] [Related]

  • 8. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, Marks PA.
    Mol Cancer Ther; 2007 Sep 15; 6(9):2525-34. PubMed ID: 17876049
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
    Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, Banks KM, Haynes NM, Gangatirkar P, Stanley K, Bolden JE, Takeda K, Yagita H, Secrist JP, Smyth MJ, Johnstone RW.
    Proc Natl Acad Sci U S A; 2008 Aug 12; 105(32):11317-22. PubMed ID: 18685088
    [Abstract] [Full Text] [Related]

  • 10. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
    Marlow LA, Bok I, Smallridge RC, Copland JA.
    Endocr Relat Cancer; 2015 Oct 12; 22(5):777-92. PubMed ID: 26206775
    [Abstract] [Full Text] [Related]

  • 11. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, Lassmann S.
    Epigenetics; 2015 Oct 12; 10(5):431-45. PubMed ID: 25923331
    [Abstract] [Full Text] [Related]

  • 12. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C, Di Gennaro E, Piro G, Milone MR, Pucci B, Caraglia M, Budillon A.
    Amino Acids; 2017 Mar 12; 49(3):517-528. PubMed ID: 27761756
    [Abstract] [Full Text] [Related]

  • 13. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
    Kortenhorst MS, Wissing MD, Rodríguez R, Kachhap SK, Jans JJ, Van der Groep P, Verheul HM, Gupta A, Aiyetan PO, van der Wall E, Carducci MA, Van Diest PJ, Marchionni L.
    Epigenetics; 2013 Sep 12; 8(9):907-20. PubMed ID: 23880963
    [Abstract] [Full Text] [Related]

  • 14. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.
    Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW.
    Proc Natl Acad Sci U S A; 2005 Mar 08; 102(10):3697-702. PubMed ID: 15738394
    [Abstract] [Full Text] [Related]

  • 15. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJ, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA, Miccolo C, Chiocca S, Kral AM, Ozerova ND, Miller TA, Methot JL, Richon VM, Secrist JP, Minucci S, Johnstone RW.
    Mol Cancer Ther; 2013 Dec 08; 12(12):2709-21. PubMed ID: 24092806
    [Abstract] [Full Text] [Related]

  • 16. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N, Cheng T, Irwin ME, Donnella H, Singh MM, Chandra J.
    Cancer Chemother Pharmacol; 2018 Mar 08; 81(3):483-495. PubMed ID: 29313067
    [Abstract] [Full Text] [Related]

  • 17. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA.
    Urol Oncol; 2013 Nov 08; 31(8):1770-9. PubMed ID: 22944197
    [Abstract] [Full Text] [Related]

  • 18. Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells.
    Fischer MA, Mustafa AM, Hausmann K, Ashry R, Kansy AG, Liebl MC, Brachetti C, Piée-Staffa A, Zessin M, Ibrahim HS, Hofmann TG, Schutkowski M, Sippl W, Krämer OH.
    J Adv Res; 2024 Jun 08; 60():201-214. PubMed ID: 37467961
    [Abstract] [Full Text] [Related]

  • 19. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
    Tabackman AA, Frankson R, Marsan ES, Perry K, Cole KE.
    J Struct Biol; 2016 Sep 08; 195(3):373-378. PubMed ID: 27374062
    [Abstract] [Full Text] [Related]

  • 20. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK, Bishayee A, Pandey AK.
    Nutrients; 2018 Jun 06; 10(6):. PubMed ID: 29882797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.